Calviri Vaccine Pipeline
Calviri is actively pursuing an integrated Pipeline of Cancer Vaccines.
This vaccine for dogs will significantly reduce cancer incidence and death without side-effects or safety concerns. Product will be priced to make it affordable in an unreimbursed, animal health market.
This vaccine will extend the health-spans and lifespans of dogs diagnosed with early-stage hemangiosarcoma (HSA). The canine MCED product will facilitate identification of early disease.
The health-spans and lifespans of patients suffering from renal medullary cancer (RMC), typically young adults with sickle cell-trait, will be extended with this vaccine. Product will be priced to make it affordable worldwide.
An inherited condition called neurofibromatosis type 1 (NF-1) is linked to the development of several cancers. The health-spans and lifespans of children suffering from NF-1 brain cancer will be extended with this vaccine. Product will be priced to make it affordable worldwide.